在细胞外GPCR纳米体中选择性和对抗性的结构基础
Roman R Schlimgen1, Francis C Peterson1, Raimond Heukers2
1Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI, 53226, USA.
Nature communications
|May 30, 2024
概括
在纳米体中扩展的CDR3循环对于准G蛋白结合受体 (GPCRs) 至关重要,比如非典型的化学因子受体3 (ACKR3). 这一发现推动了对GPCRs的纳米体药物开发.
科学领域:
- 结构生物学是结构生物学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- G蛋白结合受体 (GPCR) 是主要的药物标,但它们的复杂性阻碍了药物设计.
- 由于其独特的特性,纳米体为准GPCR提供了一个有希望的替代方案.
- 了解GPCR-纳米体相互作用对于开发新疗法至关重要.
研究的目的:
- 研究纳米体与非典型的化学因受体3 (ACKR3) 结合的结构基础.
- 将VUN701纳米体描述为ACKR3.3的对手.
- 阐明纳米体对GPCR无活化的机制.
主要方法:
- 纳米体-GPCR复合物的结构分析.
- 实验和计算方法来绘制绑定接口的地图.
- 对受体失活的合规分析.
主要成果:
- 在纳米体中扩展的CDR3循环对于ACKR3结合至关重要.
- 在VUN701纳米体抑制ACKR3功能.
- 通过纳米体相互作用定义了GPCR无活化的独特机制.
- 获得了对A类GPCR-nanobody选择性的洞察力.
结论:
- 扩展的CDR3循环是GPCR向纳米体的一个关键特征.
- VUN701-ACKR3相互作用为纳米体介导的GPCR抑制提供了一个模型.
- 这项研究为GPCRs开发基于纳米体的新疗法提供了一种策略.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
8.9K
08:21Monitoring GPCR-β-arrestin1/2 Interactions in Real Time Living Systems to Accelerate Drug Discovery
Published on: June 28, 2019
6.9K
相关概念视频
Dose-Response Relationship: Selectivity and Specificity
6.6K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
6.6K
GPCR Desensitization
6.0K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.0K
Ligand Binding Sites
12.8K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.8K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Transducer Mechanism: G Protein–Coupled Receptors
1.9K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
1.9K
